CPI-1612

• Description:

  CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity[1].

• UNSPSC:

  12352005

• Target:

  Histone Acetyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/p300-cbp-in-6.html

• Purity:

  99.74

• Solubility:

  DMSO : 230 mg/mL (ultrasonic)

• Smiles:

  O=C (NC1=NC=C (C2=CN (C) N=C2) C=C1) [C@H] (NC[C@H] (C3=CC=C (C#N) C=C3) C) C4=CC=CC=C4

• Molecular Formula:

  C27H26N6O

• Molecular Weight:

  450.53

• References & Citations:

  [1]Jonathan E Wilson, et al. Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. ACS Med Chem Lett. 2020 Apr 23;11 (6) :1324-1329.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CBP/p300

• CAS Number:

  2374971-81-8